U.S. Residential REITs Stock News

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

American Superconductor stock has given investors a very strong 3 year return, yet current valuation checks still indicate the shares trade at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and on market multiples. That combination raises questions about whether the recent share price, which closed at US$30.99, fully reflects the company’s underlying cash flow potential. American Superconductor has returned 207.7% over the past 3 years, which puts a...

Nutex Health Inc. reported past second-quarter 2026 results showing revenue of US$210.75 million versus US$243.99 million a year earlier, with net income improving to US$65.84 million from a net loss of US$17.7 million. Despite the revenue decline, the shift from loss to profit drove basic earnings per share from continuing operations to US$9.58, highlighting a sharp turnaround in profitability. Next, we’ll examine how this sharp turnaround in profitability shapes Nutex Health’s investment...

Investors in Sylvamo Corporation ( NYSE:SLVM ) had a good week, as its shares rose 5.3% to close at US$40.30 following...

Tidewater Inc. has already reported its second-quarter 2026 results, posting relatively flat revenue of US$342.29 million year on year but a lower net income of US$21.66 million, while also revising full-year 2026 revenue guidance to a range of US$1.42 billion to US$1.47 billion. Management’s comments that the offshore vessel market has stabilized at a healthy level, combined with a disciplined appetite for value-accretive M&A, highlight how Tidewater is positioning itself to potentially...

Why AMD’s latest AI moves matter for stock watchers Advanced Micro Devices (AMD) has just packed several AI related announcements into a few days, including Q2 2026 earnings, fresh revenue guidance, a new Instinct Coder inference platform and expanded data center partnerships. These events give you more concrete data points on how AMD is trying to build a fuller AI stack, from data center accelerators and infrastructure to enterprise software and PC level AI workloads. See our latest analysis...

Why Comstock Resources Stock Is Back in Focus After Q2 2026 Results Comstock Resources (CRK) is back on investors’ radar after reporting second quarter 2026 results, with lower quarterly revenue and net income, largely steady natural gas output, and weaker oil production. See our latest analysis for Comstock Resources. The stock reacted to the Q2 2026 update with a 1 day share price return of 7.08% and has a 30 day share price return of 11.15%. However, year to date it is down 39.10% and the...

Why Raymond James Financial Stock Is Back in Focus Raymond James Financial (RJF) is in the spotlight after its latest quarterly report highlighted record revenues and earnings that came in ahead of expectations, drawing fresh attention from investors. See our latest analysis for Raymond James Financial. The recent earnings beat appears to have supported positive momentum in Raymond James Financial’s share price, with a 30 day share price return of 6.53% and a 90 day share price return of...

As you might know, Relay Therapeutics, Inc. ( NASDAQ:RLAY ) last week released its latest second-quarter, and things...

Shareholders of Alpha Metallurgical Resources, Inc. ( NYSE:AMR ) will be pleased this week, given that the stock price...

Build-A-Bear Workshop, Inc. ( NYSE:BBW ), might not be a large cap stock, but it led the NYSE gainers with a relatively...

Tenable Holdings, Inc. ( NASDAQ:TENB ) recently posted some strong earnings, and the market responded positively. Our...

One thing we could say about the analysts on The Trade Desk, Inc. ( NASDAQ:TTD ) - they aren't optimistic, having just...

Palantir Technologies Inc. ( NASDAQ:PLTR ) recently posted some strong earnings, and the market responded positively...

As you might know, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) last week released its latest second-quarter, and...

Estée Lauder Companies (EL) has put fragrance in focus with Glimmer, a new prestige scent aimed at a younger consumer base. The launch offers investors a fresh data point within the company’s fragrance segment. See our latest analysis for Estée Lauder Companies. At a share price of $87.19, Estée Lauder Companies has seen short term momentum build with a 30 day share price return of 5.48%, while longer term total shareholder returns over three and five years remain well below recent highs...

Executive transition and what it may mean for Lumentum Holdings stock Lumentum Holdings (LITE) said that Vincent Retort, Executive Vice President, Global Reliability & Quality, plans to retire in October 2026 and then move into a two year consulting role with the company. For investors, this type of leadership transition in a key reliability and quality role can raise questions about continuity in operations, long term product support, and how management incentives are aligned as equity...

McEwen Inc. recently reported second-quarter 2026 results showing net income of US$9.61 million and a swing to profitability for the first half, and later revised its full-year 2026 production guidance to 109,000–120,000 gold equivalent ounces. Alongside this improved earnings profile, McEwen’s new memorandum of understanding with Paragon Advanced Labs Inc. points to a potential long-term enhancement in assay capabilities and revenue-sharing from third-party lab clients. We’ll now examine...

International Business Machines (IBM) has been in focus after a series of quantum computing milestones that include simulations of complex quantum materials, advances in error mitigation, and a large scale logical quantum computing experiment. See our latest analysis for International Business Machines. Against this backdrop of quantum milestones, International Business Machines' recent share price performance has been mixed, with the stock down about 18.9% year to date on a share price...

Pool Corporation recently declared a quarterly cash dividend of US$1.30 per share, payable on August 27, 2026 to shareholders of record as of August 13, 2026, and earlier this month presented at Deutsche Bank’s Chicago Industrials Summit in Chicago. At the same time, intensifying drought conditions in parts of England and the prospect of bans on swimming pools are raising questions about how water-use restrictions in key markets could affect demand for Pool’s products and services. Against...

What the Curium acquisition means for Lantheus investors Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) in a transaction valued at up to US$8b, offering US$102.50 in cash per share at closing plus contingent value rights worth up to US$12.00 per share. The contingent value rights are linked to commercial milestones for key Lantheus products through 2030. Until the deal closes, currently expected in the first half of 2027 subject to approvals, Lantheus will remain an independent,...

Adaptive Biotechnologies (ADPT) is back in focus after raising full year 2026 revenue guidance for its Minimal Residual Disease (MRD) business alongside its latest quarterly earnings release. See our latest analysis for Adaptive Biotechnologies. The raised MRD revenue guidance and recent earnings update appear to have coincided with a sharp shift in sentiment toward Adaptive Biotechnologies, with the stock showing a 90 day share price return of 86.72% and a 1 year total shareholder return of...

SK hynix (NasdaqGS:SKHY) approved a roughly US$38b program to build new high bandwidth memory focused fabs in South Korea, a large expansion that brings long term capital commitments into sharper focus for current and potential shareholders. See our latest analysis for SK hynix. Despite the expansion plans and supportive policy moves around South Korea's semiconductor sector in recent weeks, SK hynix's 30 day share price return is down 19.48%, and the year to date share price return matches...

What Erasca’s New R&D Leadership Could Mean for Investors Erasca (ERAS) has drawn fresh attention after appointing Charles S. Fuchs, M.D., M.P.H., as president of research and development, bringing extensive oncology and biopharma leadership into the company’s clinical stage pipeline. For investors, this leadership change raises practical questions. How might a veteran with experience at Genentech, Roche, Tubulis, and major academic centers influence research priorities, partnership choices,...